HRP20121044T1 - Novi postupak za sintetiziranje ivabradina i njegovih adicijskih soli s farmaceutski prihvatljivom kiselinom - Google Patents
Novi postupak za sintetiziranje ivabradina i njegovih adicijskih soli s farmaceutski prihvatljivom kiselinom Download PDFInfo
- Publication number
- HRP20121044T1 HRP20121044T1 HRP20121044AT HRP20121044T HRP20121044T1 HR P20121044 T1 HRP20121044 T1 HR P20121044T1 HR P20121044A T HRP20121044A T HR P20121044AT HR P20121044 T HRP20121044 T HR P20121044T HR P20121044 T1 HRP20121044 T1 HR P20121044T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- formula
- compound
- acids
- vii
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 12
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims 5
- 229960003825 ivabradine Drugs 0.000 title claims 5
- 239000002253 acid Substances 0.000 title claims 4
- 150000003839 salts Chemical class 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 25
- 230000015572 biosynthetic process Effects 0.000 claims 11
- 238000003786 synthesis reaction Methods 0.000 claims 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- 238000006268 reductive amination reaction Methods 0.000 claims 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 3
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 3
- 235000010323 ascorbic acid Nutrition 0.000 claims 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 3
- 235000015165 citric acid Nutrition 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 235000011090 malic acid Nutrition 0.000 claims 3
- 230000003287 optical effect Effects 0.000 claims 3
- 235000006408 oxalic acid Nutrition 0.000 claims 3
- 229940107700 pyruvic acid Drugs 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 150000000996 L-ascorbic acids Chemical class 0.000 claims 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 150000008107 benzenesulfonic acids Chemical class 0.000 claims 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 150000002913 oxalic acids Chemical class 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- 239000010948 rhodium Substances 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000008096 xylene Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (12)
1. Proces sinteze spoja formule (VI) u racemičnom ili optički aktivnom obliku:
[image]
gdje A predstavlja H2C-CH2 ili HC=CH, naznačen time, da je spoj formule (VII) u racemičnom ili optičkom aktivnom obliku:
[image]
izložen reduktivnoj aminacijskoj reakciji sa spojem formule (VIII) :
[image]
pri čemu je A prethodno definiran, u nazočnosti redukcijskog sredstva u organskom otapalu ili smjesi organskih otapala.
2. Proces sinteze u skladu s patentnim zahtjevom 1, naznačen time, da je spoj formule (VII) u optički aktivnom obliku i posebice ima konfiguraciju (S).
3. Proces sinteze u skladu s patentnim zahtjevom 2, naznačen time, da skupina A predstavlja H2C-CH2 a produkt reduktivne aminacijske reakcije spoja formule (VII) sa spojem formule (VIII) je ivabradin formule (I):
[image]
koji po izboru može biti konvertiran u adicijske soli s farmaceutski prihvatljivom kiselinom odabranom od klorovodične kiseline, bromovodične kiseline, sumporne kiseline, fosforne kiseline, octene kiseline, trifluoroctene kiseline, mliječne kiseline, piruvinske kiseline, malonske kiseline, sukcinske kiseline, glutarne kiseline, fumarne kiseline, tartarne kiseline, jabučne kiseline, limunske kiseline, askorbinske kiseline, oksalne kiseline, metansulfonske kiseline, benzenesulfonske kiseline i kamforne kiseline te u njihove hidrate.
4. Proces sinteze u skladu s patentnim zahtjevom 2, naznačen time, da skupina A predstavlja HC=CH a produkt reduktivne aminacijske reakcije spoja formule (VII) sa spojem formule (VIII) je spoj formule (V):
[image]
katalitička hidrogenacija od koje se dobiva ivabradin formule (1) :
[image]
koji po izboru može biti konvertiran u svoje adicijske soli s farmaceutski prihvatljivom kiselinom odabranom od klorovodične kiseline, bromovodične kiseline, sumporne kiseline, fosforne kiseline, octene kiseline, trifluoroctene kiseline, mliječne kiseline, piruvinske kiseline, malonske kiseline, sukcinske kiseline, glutarne kiseline, fumarne kiseline, tartarne kiseline, jabučne kiseline, limunske kiseline, askorbinske kiseline, oksalne kiseline, metansulfonske kiseline, benzensulfonske kiseline i kamforne kiseline, te u njihove hidrate.
5. Proces sinteze u skladu s patentnim zahtjevom 1, naznačen time, da je spoj formule (VII) u racemičnom obliku a reduktivna aminacijska reakcija spoja formule (VII) sa spojem formule (VIII) praćena je korakom optičke rezolucije dobivenog racemičnog spoja formula (VI).
6. Proces sinteze u skladu s patentnim zahtjevom 5, naznačen time, da A predstavlja H2C-CH2 a produkt dobiven nakon koraka optičke rezolucije spoja formule (VI) je ivabradin formule (I) :
[image]
7. Proces sinteze u skladu s patentnim zahtjevom 5, naznačen time, da A predstavlja HC=CH a produkt dobiven nakon koraka optičke rezolucije spoja formule (VI) je spoj formule (V) :
[image]
katalitička hidrogenacija kojom se dobiva ivabradin formule (I):
[image]
koji po izboru može biti konvertiran u svoje adicijske soli s farmaceutski prohvatljivom kiseline odabranom od klorovodične kiseline, bromovodične kiseline, sumporne kiseline, fosforne kiseline, octene kiseline, trifluoroctene kiseline, mliječne kiseline, piruvinske kiseline, malonske kiseline, sukcinske kiseline, glutarne kiseline, fumarne kiseline, tartarne kiseline, jabučne kiseline, limunske kiseline, askorbinske kiseline, oksalne kiseline, metansulfonske kiseline, benzensulfonske kiseline i kamforne kiseline i u njihove hidrate.
8. Proces sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da je redukcijsko sredstvo korišteno za izvođenje reduktivne aminacijske reakcije spoja formule (VII) sa spojem formule (VIII) odabrano od natrij triacetoksiborohidrida, natrij cijanoborohidrida i dihidrogena u nazočnosti katalizatora kao što je paladij, platina, nikl, rutenij, rodij i njihovi derivati, posebice u podržanom obliku ili obliku oksida.
9. Proces sinteze u skladu s patentnim zahtjevom 8, naznačen time, da je redukcijsko sredstvo korišteno za izvođenje reduktivne aminacijske reakcije spoja formule (VII) sa spojem formule (VIII) natrij triacetoksiborohidrid.
10. Proces sinteze u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time, da je otapalo koje je korišteno za izvođenje reduktivne aminacijske reakcije spoja formule (VII) sa spojem formule (VIII) odabrano od tetrahidrofurana, diklormetana, 1,2-dikloretana, acetata, alkohola, poželjno je, etanola, metanola ili izopropanola, toluena i ksilena.
11. Proces sinteze u skladu s patentnim zahtjevom 10, naznačen time, da je otapalo koje je korišteno u reduktivnoj aminacijskoj reakciji spoja formule (VII) sa spojem formule (VIII) konstituirano putem smjese tetrahidrofurana i diklormetana.
12. Spoj formule (VII), naznačen time, da je u racemičnom ili optički aktivnom obliku:
[image]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0807444A FR2940287B1 (fr) | 2008-12-24 | 2008-12-24 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121044T1 true HRP20121044T1 (hr) | 2013-01-31 |
Family
ID=40823411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121044AT HRP20121044T1 (hr) | 2008-12-24 | 2012-12-18 | Novi postupak za sintetiziranje ivabradina i njegovih adicijskih soli s farmaceutski prihvatljivom kiselinom |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8097720B2 (hr) |
| EP (1) | EP2202225B1 (hr) |
| JP (1) | JP5276579B2 (hr) |
| KR (1) | KR101064413B1 (hr) |
| CN (1) | CN101759643B (hr) |
| AR (1) | AR074845A1 (hr) |
| AU (1) | AU2009245875B2 (hr) |
| BR (1) | BRPI0905147A8 (hr) |
| CA (1) | CA2688815C (hr) |
| CL (1) | CL2009002201A1 (hr) |
| DK (1) | DK2202225T3 (hr) |
| EA (1) | EA016405B1 (hr) |
| ES (1) | ES2398332T3 (hr) |
| FR (1) | FR2940287B1 (hr) |
| GE (1) | GEP20125491B (hr) |
| HK (1) | HK1145833A1 (hr) |
| HR (1) | HRP20121044T1 (hr) |
| JO (1) | JO2807B1 (hr) |
| MA (1) | MA31498B1 (hr) |
| ME (1) | ME02037B (hr) |
| MX (1) | MX2009013480A (hr) |
| MY (1) | MY148288A (hr) |
| NZ (1) | NZ582310A (hr) |
| PA (1) | PA8855501A1 (hr) |
| PE (1) | PE20100487A1 (hr) |
| PL (1) | PL2202225T3 (hr) |
| PT (1) | PT2202225E (hr) |
| RS (1) | RS52542B (hr) |
| SA (1) | SA109310011B1 (hr) |
| SG (1) | SG162671A1 (hr) |
| SI (1) | SI2202225T1 (hr) |
| TW (1) | TWI385153B (hr) |
| UA (1) | UA102518C2 (hr) |
| UY (1) | UY32311A (hr) |
| WO (1) | WO2010072930A1 (hr) |
| ZA (1) | ZA200909109B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5632279B2 (ja) | 2007-05-30 | 2014-11-26 | アイエヌディー−スイフト ラボラトリーズ リミテッド | 塩酸イバブラジンの調製方法及びポリモルフ |
| US11164672B2 (en) | 2010-01-22 | 2021-11-02 | Deka Products Limited Partnership | System and apparatus for electronic patient care |
| US11244745B2 (en) | 2010-01-22 | 2022-02-08 | Deka Products Limited Partnership | Computer-implemented method, system, and apparatus for electronic patient care |
| US11210611B2 (en) | 2011-12-21 | 2021-12-28 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
| US20110313789A1 (en) | 2010-01-22 | 2011-12-22 | Deka Products Limited Partnership | Electronic patient monitoring system |
| US10453157B2 (en) | 2010-01-22 | 2019-10-22 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
| US11881307B2 (en) | 2012-05-24 | 2024-01-23 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
| US10911515B2 (en) | 2012-05-24 | 2021-02-02 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
| CN102464595B (zh) * | 2010-11-17 | 2015-02-25 | 山东新时代药业有限公司 | 一种伊伐布雷定中间体的合成方法 |
| FR2971507B1 (fr) * | 2011-02-14 | 2013-01-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| EP2495237A1 (en) | 2011-03-04 | 2012-09-05 | Alembic Pharmaceuticals Limited | An improved process for the preparation of highly pure ivabradine hydrochloride |
| FR2984320B1 (fr) * | 2011-12-20 | 2013-11-29 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2984319B1 (fr) * | 2011-12-20 | 2013-12-27 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| CN103848789B (zh) * | 2012-11-29 | 2016-05-18 | 江苏恒瑞医药股份有限公司 | 一种伊伐布雷定的制备方法 |
| CN103864690B (zh) * | 2014-01-06 | 2016-09-14 | 北京莱瑞森医药科技有限公司 | 伊伐布雷定盐酸盐的s晶型、其制备方法和药物组合物 |
| EP3101010A1 (en) | 2015-06-03 | 2016-12-07 | Urquima S.A. | New method for the preparation of highly pure ivabradine base and salts thereof |
| CN113372273B (zh) * | 2020-03-10 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定中间体化合物iv |
| CN113372274B (zh) * | 2020-03-10 | 2023-03-24 | 鲁南制药集团股份有限公司 | 一种伊伐布雷定的制备方法 |
| JP7108650B2 (ja) | 2020-03-11 | 2022-07-28 | 株式会社カナモト | 車両の自動遠隔操縦装置 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2870537A1 (fr) * | 2004-05-19 | 2005-11-25 | Servier Lab | Nouveau procede de synthese du (1s)-4,5-dimethoxy-1-(methyl aminomethyl-)-benzocyclobutane et de ses sels d'addition, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| ATE544754T1 (de) * | 2006-11-30 | 2012-02-15 | Cadila Healthcare Ltd | Verfahren zur herstellung von ivabradinhydrochlorid |
| JP5632279B2 (ja) * | 2007-05-30 | 2014-11-26 | アイエヌディー−スイフト ラボラトリーズ リミテッド | 塩酸イバブラジンの調製方法及びポリモルフ |
-
2008
- 2008-12-24 FR FR0807444A patent/FR2940287B1/fr not_active Expired - Fee Related
-
2009
- 2009-12-04 SG SG200908061-5A patent/SG162671A1/en unknown
- 2009-12-04 PE PE2009001290A patent/PE20100487A1/es active IP Right Grant
- 2009-12-08 UY UY0001032311A patent/UY32311A/es not_active Application Discontinuation
- 2009-12-09 AU AU2009245875A patent/AU2009245875B2/en not_active Ceased
- 2009-12-10 MX MX2009013480A patent/MX2009013480A/es active IP Right Grant
- 2009-12-10 CA CA2688815A patent/CA2688815C/fr not_active Expired - Fee Related
- 2009-12-11 MY MYPI20095312A patent/MY148288A/en unknown
- 2009-12-16 MA MA32424A patent/MA31498B1/fr unknown
- 2009-12-17 JO JO2009485A patent/JO2807B1/en active
- 2009-12-17 TW TW098143420A patent/TWI385153B/zh not_active IP Right Cessation
- 2009-12-18 EA EA200901563A patent/EA016405B1/ru not_active IP Right Cessation
- 2009-12-18 GE GEAP200911610A patent/GEP20125491B/en unknown
- 2009-12-21 ZA ZA200909109A patent/ZA200909109B/en unknown
- 2009-12-22 CL CL2009002201A patent/CL2009002201A1/es unknown
- 2009-12-22 UA UAA200913368A patent/UA102518C2/ru unknown
- 2009-12-22 SA SA109310011A patent/SA109310011B1/ar unknown
- 2009-12-22 AR ARP090105037A patent/AR074845A1/es not_active Application Discontinuation
- 2009-12-23 SI SI200930409T patent/SI2202225T1/sl unknown
- 2009-12-23 ES ES09290990T patent/ES2398332T3/es active Active
- 2009-12-23 WO PCT/FR2009/001480 patent/WO2010072930A1/fr active Application Filing
- 2009-12-23 CN CN2009102636114A patent/CN101759643B/zh not_active Expired - Fee Related
- 2009-12-23 ME MEP-2012-526A patent/ME02037B/me unknown
- 2009-12-23 PA PA20098855501A patent/PA8855501A1/es unknown
- 2009-12-23 RS RS20120526A patent/RS52542B/en unknown
- 2009-12-23 US US12/655,087 patent/US8097720B2/en not_active Expired - Fee Related
- 2009-12-23 NZ NZ582310A patent/NZ582310A/en not_active IP Right Cessation
- 2009-12-23 BR BRPI0905147A patent/BRPI0905147A8/pt not_active IP Right Cessation
- 2009-12-23 DK DK09290990.2T patent/DK2202225T3/da active
- 2009-12-23 EP EP09290990A patent/EP2202225B1/fr active Active
- 2009-12-23 PT PT09290990T patent/PT2202225E/pt unknown
- 2009-12-23 PL PL09290990T patent/PL2202225T3/pl unknown
- 2009-12-24 JP JP2009291676A patent/JP5276579B2/ja active Active
- 2009-12-24 KR KR1020090130714A patent/KR101064413B1/ko active IP Right Grant
-
2010
- 2010-12-29 HK HK10112196.5A patent/HK1145833A1/xx not_active IP Right Cessation
-
2012
- 2012-12-18 HR HRP20121044AT patent/HRP20121044T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121044T1 (hr) | Novi postupak za sintetiziranje ivabradina i njegovih adicijskih soli s farmaceutski prihvatljivom kiselinom | |
| US5254569A (en) | (Amidomethyl)nitrogen heterocyclic analgesics | |
| AU2009208068B2 (en) | New process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile and application in the synthesis of Ivabradine | |
| HRP20100024T1 (hr) | Postupak priprave derivata 1,3,4,5-tetrahidro-2h-3-benzepin-2-ona, njihova primjena u sintezi ivabradina i njihove farmaceutski prihvatljive soli | |
| EA201170811A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ЭТИЛОВОГО ЭФИРА ТРАНС-4-АМИНОЦИКЛОГЕКСИЛУКСУСНОЙ КИСЛОТЫ∙HCl | |
| CN107098849A (zh) | 一种盐酸左布比卡因的制备方法 | |
| NZ598354A (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| TWI430993B (zh) | 合成依伐布雷定（ｉｖａｂｒａｄｉｎｅ）及其與醫藥上可接受酸之加成鹽之新穎方法 | |
| DK3077354T3 (en) | NEW PROCEDURE FOR SYNTHESIS OF AGOMELATIN | |
| NO134055B (hr) | ||
| CN104837817B (zh) | 制备3‑氨基‑哌啶化合物的合成路线 | |
| CN103896795A (zh) | 甲酰胺化合物、其中间体的制备方法及其用途 | |
| EP3578545B1 (en) | Method for producing optically active pyrrolidine compounds | |
| DD202711A5 (de) | Verfahren zur herstellung von (thienyl-2)- und (thienyl-3)-2-ethylaminen | |
| CN102140068A (zh) | 阿利吉仑中间体3-氨基-2，2-二甲基丙酰胺的制备方法 | |
| CN112552184B (zh) | 一种含环丙基手性胺盐酸盐的合成方法 | |
| CN104098485A (zh) | 一种邻氨基苯羟胺的制备方法 | |
| ITMI20090311A1 (it) | Procedimento per la preparazione di intermedi chetonici | |
| CA2968770A1 (en) | A process for the manufacture of idalopirdine | |
| WO2008059525A2 (en) | An improved process for the preparation of venlafaxine and its analogs | |
| CN101555223A (zh) | 一种吡利霉素中间体及其制备方法 | |
| Griffin et al. | Delta agonist hydroxy bioisosteres: The discovery of 3-((1-benzylpiperidin-4-yl){4-[(diethylamino) carbonyl] phenyl} amino) benzamide with improved delta agonist activity and in vitro metabolic stability | |
| HRP20160200T1 (hr) | Novi postupak za sintezu 3-(2-brom-4,5-dimetoksifenil)propanonitrila i uporaba za sintezu ivabradina i dodanih soli s farmaceutski prihvatljivom kiselinom | |
| ITMI20100770A1 (it) | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi | |
| EP3440055B1 (en) | A process for the manufacture of idalopirdine via hydrogenation of an imine |